Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Exelixis And BMS Advance Collaboration
by Rick Mullin
December 22, 2008
| A version of this story appeared in
Volume 86, Issue 51
Exelixis, a South San Francisco-based biopharmaceutical firm, and Bristol-Myers Squibb have formed a drug development collaboration covering two Exelixis small molecules for cancer: XL184, a thyroid cancer therapy in Phase III clinical trials, and XL281, a treatment for advanced solid tumors in Phase I trials. Under the agreement, BMS will pay Exelixis $195 million up front for rights to both programs and make additional license payments of $45 million in 2009. The companies have collaborated for nearly a decade.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter